News & Updates

Show Multimedia Only

177Lu-Dotatate boosts PFS in Asian patients with advanced GEP-NETs

04 Feb 2026 by

Peptide receptor radionuclide therapy (PRRT) with lutetium-177 (¹⁷⁷Lu)-Dotatate significantly improved progression-free survival (PFS) among Asian patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs), according to the LUMINET-1 study presented at ESMO Asia 2025.

177Lu-Dotatate boosts PFS in Asian patients with advanced GEP-NETs

04 Feb 2026

Nocturnal hypertension tied to poorer cardiovascular outcomes among seniors

03 Feb 2026

Among patients of very advanced age, those with nocturnal hypertension are at increased risk of adverse cardiovascular outcomes, as reported in a study.

Nocturnal hypertension tied to poorer cardiovascular outcomes among seniors

03 Feb 2026

Investigational oral antibiotic noninferior to dual therapy for uncomplicated gonorrhoea

03 Feb 2026 by

In the treatment of uncomplicated urogenital gonorrhoea, a single dose of the novel oral antibiotic zoliflodacin shows similar efficacy and safety profile as the ceftriaxone plus azithromycin combination, as shown in a multinational phase III study.

Investigational oral antibiotic noninferior to dual therapy for uncomplicated gonorrhoea

03 Feb 2026

12 risk factors linked to postoperative VTE in gynaecologic malignancy patients

03 Feb 2026

Several factors tend to increase the risk of venous thromboembolism (VTE) in patients with gynaecologic malignant tumours after surgery, reveals a study.

12 risk factors linked to postoperative VTE in gynaecologic malignancy patients

03 Feb 2026

Liver supplements popularity on the rise despite limited evidence

03 Feb 2026 by

The market for liver supplements is rapidly growing despite lacking scientific evidence to support their efficacy claims, reveals a study.

Liver supplements popularity on the rise despite limited evidence

03 Feb 2026

Does MetS induce fibrosis progression/regression?

03 Feb 2026

Metabolic syndrome (MetS) appears to contribute to greater histological severity in patients with nonalcoholic fatty liver disease (NAFLD) but does not seem to influence disease progression or regression, according to a study.

Does MetS induce fibrosis progression/regression?

03 Feb 2026

NATALEE updates: Ribociclib benefit in HR+, ERBB– EBC sustained at 4 years

03 Feb 2026 by

In an updated analysis of the NATALEE* trial, the efficacy benefit of adjuvant ribociclib remains consistent even after the planned 3-year treatment duration for patients with HR+, ERBB2– early breast cancer (EBC).

NATALEE updates: Ribociclib benefit in HR+, ERBB– EBC sustained at 4 years

03 Feb 2026

Finerenone a viable option in primary aldosteronism treatment

03 Feb 2026

The novel nonsteroidal mineralocorticoid receptor antagonist finerenone appears safe and efficacious in the treatment of primary aldosteronism, as shown in a study.

Finerenone a viable option in primary aldosteronism treatment

03 Feb 2026

10-year data support antibiotics treatment of uncomplicated acute appendicitis

02 Feb 2026 by

Among adults who received antibiotic treatment for uncomplicated acute appendicitis in the APPAC* trial, the number of recurrences and subsequent appendectomies at 10 years demonstrates the viability of this nonsurgical treatment approach, as reported by the investigators.

10-year data support antibiotics treatment of uncomplicated acute appendicitis

02 Feb 2026

Semaglutide superior to dulaglutide, liraglutide for glycaemic control, weight loss in T2D

02 Feb 2026

Treatment with semaglutide appears more effective than both dulaglutide and liraglutide for glycaemic control and weight loss in patients with type 2 diabetes (T2D), reports a China study. On the other hand, dulaglutide and liraglutide show similar clinical efficacy.

Semaglutide superior to dulaglutide, liraglutide for glycaemic control, weight loss in T2D

02 Feb 2026

News & Updates

Showing Multidisciplinary articles

Showing

Specialty:

177Lu-Dotatate boosts PFS in Asian patients with advanced GEP-NETs

177Lu-Dotatate boosts PFS in Asian patients with advanced GEP-NETs

Nocturnal hypertension tied to poorer cardiovascular outcomes among seniors

Nocturnal hypertension tied to poorer cardiovascular outcomes among seniors

Investigational oral antibiotic noninferior to dual therapy for uncomplicated gonorrhoea

Investigational oral antibiotic noninferior to dual therapy for uncomplicated gonorrhoea

12 risk factors linked to postoperative VTE in gynaecologic malignancy patients

12 risk factors linked to postoperative VTE in gynaecologic malignancy patients

Liver supplements popularity on the rise despite limited evidence

Liver supplements popularity on the rise despite limited evidence

Does MetS induce fibrosis progression/regression?

Does MetS induce fibrosis progression/regression?

NATALEE updates: Ribociclib benefit in HR+, ERBB– EBC sustained at 4 years

NATALEE updates: Ribociclib benefit in HR+, ERBB– EBC sustained at 4 years

Finerenone a viable option in primary aldosteronism treatment

Finerenone a viable option in primary aldosteronism treatment

10-year data support antibiotics treatment of uncomplicated acute appendicitis

10-year data support antibiotics treatment of uncomplicated acute appendicitis

Semaglutide superior to dulaglutide, liraglutide for glycaemic control, weight loss in T2D

Semaglutide superior to dulaglutide, liraglutide for glycaemic control, weight loss in T2D